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Common to other practice settings, standard in vitro fertilisation (IVF) in California 
strongly skews the multiple gestation/preterm birth rate upward to approximately 50% of 
all deliveries, while unassisted conceptions yield this outcome in only 3% of births. 
Preterm/multiple gestation babies from IVF are “super-utilisers” and consume a 
disproportionate share of healthcare resources, particularly during the first year of life. 
However, early experience with molecular cytogenetic techniques has shown that single 
embryo transfer (SET) with IVF can now lift pregnancy rates to an acceptable level 
while not altering the normal multiple gestation rate. This approach would effectively 
solve the preterm and multiple gestation problem historically associated with IVF.  
 
Building on the author’s previous research in medically assisted reproduction, the 
current proposal describes a new public health policy to incentivise SET by modifying 
the California Insurance Code (benchmark health plan), when it may next be revised in 
2015. The proposal would partially cover IVF costs for qualified California residents 
with the proviso that only one embryo is transferred per procedure after comprehensive 
chromosomal screening of embryos with array comparative genomic hybridisation 
(aCGH). This investigation considers the interconnected problems of preterm birth and 
multiple gestation in a demographic context, showing that although the contribution 
made by conventional IVF to these adverse outcomes in California is numerically minor, 
substantial costs can still be recovered by redirecting expenditures away from high-risk 
IVF deliveries when the increased multiple gestation/preterm birth rate from standard 
IVF is corrected. 
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This analysis is the first to examine costs calculated for all delivery types in California as 
a function of antecedent IVF treatment vs. unassisted conception, based on 2009 birth 
records, and apply this to a new model of comprehensive embryo testing and mandatory 
SET. These data reveal that even if partially subsidised IVF with aCGH and SET were 
provided for every California IVF cycle initiated in 2009 (n=18,405), the state would 
still realise a net surplus of at least $20M per year by stabilising the IVF multiple birth 
rate at ∼3.2%. Thus, California can avoid up to 4,810 iatrogenic preterm/multiple 
gestation births by shifting the prevailing approach to IVF away from multiple embryo 
transfers. The proposal is net revenue positive for California because although IVF with 
aCGH and SET is expensive, the price to obtain this technology is always lower than the 
cost for one high-risk preterm/multiple birth. While a compelling primary interest exists 
to lower the multiple birth rate with IVF, this proposal also yields a socially valuable 
secondary public health benefit by improving general access to this advanced 





To optimise effectiveness in public health spending in California by lowering the 
proportion of multiple gestation and preterm births from in vitro fertilisation (IVF) in the 
state, and to equalise access to IVF for all Californians.  
 
Objectives 
The following objectives will be informed by evidence primarily sourced from the 
author’s published works and, where appropriate, corroborated with the work of others: 
 
1. To review the process of IVF and to review customary funding structures for IVF in 
California with an emphasis on how this might be affected by recent changes in health 
care funding, 
 
2. To calculate IVF’s contribution to multiple births and preterm delivery in California, 
and measure the economic impact of these outcomes, 
 
3. To establish how single embryo transfer (SET) attenuates the problem of multiple 
births and preterm delivery associated with IVF, and 
 
4. To forecast the recovery of health spend in the context of SET if IVF were partially 




1. Introduction & Background 
 
Public interest in American healthcare reform was crystallised in the recent enactment of 
the Patient Protection & Affordable Care Act, 2010 (also known as PPACA or 
“Obamacare”). While offering essential healthcare coverage for most Americans is the 
chief aim of this landmark legislation, PPACA also provides an opportunity to resolve 
two longstanding and closely related health policy challenges affecting a special 
population: to reverse the rising rates of higher-order multiple gestation/preterm births, 
and to improve general access to in vitro fertilisation (IVF). These two objectives seem 
to reflect a conflicted, intractable healthcare dilemma, because making IVF (and its 
customary multiple embryo transfers) more available can be reasonably expected to 
exacerbate multiple gestation and preterm delivery rates. 
 
Delivery of a healthy singleton live birth is the ideal outcome for all medical infertility 
treatment. During in vitro fertilisation (IVF), multiple embryos are typically transferred 
because any individual embryo may contain serious chromosomal error, which can result 
in implantation failure or spontaneous abortion (Sills et al., 2012b). Strategies to 
improve embryo implantation have included sequential (compound) transfer, whereby 
embryos are transferred on more than one day (Hayrinen et al., 2012), although this is 
not routine practice. For each IVF patient who undergoes transfer of more than one 
embryo at a time—which is the great majority of cases—her treatment culminates with 
the hope that at least one embryo will successfully implant and bring a healthy 
pregnancy. Generally, IVF embryos are chosen for transfer based on their appearance as 
determined by microscopic examination. Selecting embryos for transfer based on 
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morphologic criteria alone is imprecise, because there is essentially no correlation 
between the embryo’s appearance (morphology during the first several days after 
fertilisation) and its genomic status (Alfarawati et al., 2011). For example, a significant 
proportion of aneuploid embryos will demonstrate the highest morphologic score, while 
some euploid embryos will be of inferior morphology (Alfarawati et al., 2011). Even the 
most junior embryologist quickly notes how the transfer of poor quality embryos can 
result in healthy IVF babies, yet normal looking embryos fail to implant after transfer 
(Sills et al., 2012b). Recently, the continuous morphological evaluation by uninterrupted 
video monitoring of embryos during in vitro culture has been proposed as a way to 
address some of the shortcomings of standard embryo scoring systems (Campbell et al., 
2013). While this approach does offer a fuller picture of early embryo morphokinetics, 
chromosomal competency of embryos cannot be ascertained by this method. Thus, 
visually picking the “right” embryo for transfer in IVF remains a high stakes challenge, 
since less than 15% of embryos may actually implant and grow into healthy infants (U.S. 
Centers for Disease Control and Prevention, 2008).  
 
Against this background, any expectation that standard microscopic examination of 
embryos could secure any meaningful surveillance of genetic error before transfer is 
unrealistic; the traditional practice to select by morphology helps explain why the 
efficiency of single embryo transfer protocols has remained so low. Since many IVF 
patients will accept a higher twinning risk in exchange for a meaningful reduction in 
overall treatment failure (Pinborg et al., 2003; Højgaard et al., 2007), multiple embryo 
transfer has emerged as the mainstream clinical response to this challenge (Sills et al., 
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2009d). Following this approach, some IVF patients may conclude their treatment with a 
singleton gestation despite multiple embryos being transferred. Yet, the IVF patient who 
undergoes transfer of multiple embryos must be prepared for one of two very unsettling 
outcomes. Either she will not conceive at all, or a multiple gestation will result—the 
degree of multiple gestation and preterm birth being determined by how many embryos 
were transferred (Kern, 2009; Sills et al., 2012b). This latter circumstance poses 
significant risk both for mother and offspring, including increased incidence of 
preeclampsia, postpartum hemorrhage, hysterectomy and gestational diabetes (Walker et 
al., 2004), as well as greater risk of preterm delivery, low birthweight infants, cerebral 
palsy and congenital malformations (Bergh et al., 1999; Sills & Palermo, 2002a; 
Stromberg et al., 2002; Pinborg et al., 2003).  
 
The health benefits of a single embryo transfer approach were dramatically revealed by a 
Danish study of IVF outcomes, where cerebral palsy incidence was measured among 
1,042 IVF singletons born after only one embryo was transferred. Just one of those 
babies received a cerebral palsy diagnosis, compared with 21 cerebral palsy cases among 
IVF singletons born after two or more embryo transfers (Hvidtjørn et al., 2010). In 
Canada, efforts to mandate single embryo transfer gained momentum when this change 
in IVF practice was shown to prevent infant deaths and reduce serious complications 
associated with multiple gestations (Voelker, 2011). Such research illustrates how IVF 
babies comprise an important class of healthcare ‘super-utilisers’ (Koivurova et al., 
2007). Indeed, a recent study of NICU admissions at one hospital found 75 of 82 infants 
to be twins or triplets whose mothers relied on IVF to become pregnant. Among those 75 
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babies there were six deaths, and five more developed severe brain hemorrhage (Voelker, 
2011). Such statistics for multiple gestation and preterm birth trace a similar arc as 
closely interrelated consequences of increased IVF use. Notwithstanding the devastating 
emotional impact these tragic outcomes have on patients and their families, the fiscal 
burden on hospital resources is enormous.  
 
Clearly, any public health effort to tackle the alarming costs of multiple gestation and 
preterm birth will have diminished effectiveness without recognising IVF’s contribution 
to the problem. The most obvious remedy for multiple gestation in the setting of IVF is 
single embryo transfer, but several factors including an unfavorable reimbursement 
system have hindered the uptake of this approach (van Peperstraten et al., 2008).  
 
This original research places one of these new technologies, array comparative genomic 
hybridisation (aCGH), at the center of a treatment initiative designed to address the 
intertwined healthcare issues of excessive rates of multiple gestation and preterm birth 
from IVF, while at the same time improving access to this treatment recognised as 
highly effective in the struggle against infertility. This proposal entails embryo biopsy 
performed on day five and SET the next day, rather than requiring an embryo transfer be 
undertaken later in a subsequent frozen transfer cycle. Array CGH has been refined 
(Sills et al., 2012b) and awaits recognition by government and insurance as a way to 




2. Limitations of Conventional IVF 
For IVF patients, becoming a parent hinges on the successful completion of a medical 
odyssey comprising a fretful maze of tests and expensive procedures (Sills et al., 2010c). 
The complexity and high cost of IVF relates to the interlock of ovarian screening, 
clinical management during oocyte development, laboratory incubation/culture, and 
embryo transfer. At present, treatment effectiveness is low especially for older IVF 
patients with success rates adversely impacted by ovarian ageing (Sills et al., 2009e). 
Transferring three or more embryos at a time is a common way to address the problem 
of poor embryo implantation in such cases, although oocyte donation may also be 
considered (Sills et al., 2010a,b,c). 
 
In general, procedures or treatments which include the laboratory (in vitro) manipulation 
of human spermatozoa, oocytes, or embryos for the purpose of achieving pregnancy are 
classified as advanced reproductive techniques (Zegers-Hochschild et al., 2009). A 
typical IVF cycle consists of ovulation induction with injectable gonadotropins to recruit 
multiple mature oocytes, surgical removal of the mature eggs under anaesthesia, 
fertilisation of eggs under controlled laboratory conditions to build embryos (Sills & 
Palermo, 2010), and the transfer of embryos to the uterine interior. Non-transferred 
(surplus) embryos which remain after fresh transfer may be cryopreserved, with 
subsequent thaw and transfer to the patient at some later date (Sills et al., 2008; Sills & 
Murphy, 2009; Sills et al., 2009b). For all patients seeking this elective fertility 
treatment, only about 20% of IVF attempts (either fresh or frozen) will result in a 
livebirth (Chambers et al., 2012). 
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Not every patient who wishes to do IVF will be medically suitable for this treatment, so 
pre-enrolment testing is essential. This is because fertility potential first declines after 
age 30 and moves downward rapidly thereafter, essentially reaching zero by the mid-40s 
(Sills et al., 2009a). The concept of ovarian reserve describes the natural oocyte 
endowment and is closely associated with female age, which is the single most important 
factor influencing reproductive outcome. Conceptions at advanced age are exceedingly 
rare even with IVF, unless oocytes obtained from a younger donor are utilised (Sills et 
al., 2010b). How best to measure ovarian reserve remains an area of active research 
(Sills et al., 2009a). Passive assessments of ovarian reserve include measurement of 
serum follicle stimulating hormone (FSH), oestradiol (E2), anti-Müllerian hormone (Sills 
et al., 2011), and inhibin-B. Ultrasound determination of antral follicle count (AFC), 
ovarian vascularity and ovarian volume may also have a role. The clomiphene citrate 
challenge test (CCCT), exogenous FSH ovarian reserve test (EFORT), and GnRH-
agonist stimulation test (GAST) are provocative methods which may be helpful in 
assessing ovarian reserve (Sills et al., 2009a). Importantly, an IVF patient's prior 
response to gonadotropins also provides highly valuable information about ovarian 
function (Sills et al., 1998). 
 
These tests are complemented by the male factor evaluation, also a critical part of basic 
fertility screening. A standard semen analysis is essential to a thorough reproductive 
work-up. Recently, other more sophisticated andrology testing has been described to 
supplement the basic semen analysis before commencing IVF, including assessment of 
nuclear (sperm) chromatin fragmentation (Sills et al., 2004; Bungum et al., 2012). As 
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with the female, a general endocrine evaluation may also be indicated for the male since 
hormonal disruption in the man can impair semen parameters (Saie & Sills, 2005). 
 
Fertility patients not conceiving after multiple IVF attempts typically face a difficult 
prognosis. The impact of increased refractoriness to IVF on reproductive outcome 
following transfer of blastocysts (day 5 embryos) has been studied among patients with a 
history of repetitive failed day three embryo transfers (Walsh et al., 2009b). There is no 
consensus guiding medical decisions after such multiple IVF failures (Tan et al., 2005), 
but maternal endocrine, anatomic, immunologic, infectious, and genetic parameters are 
typically investigated (Christiansen et al., 2006). In circumstances where immunological 
pathology is suspected as a cause for recurrent miscarriage, corrective therapies can 
result in pregnancy and healthy delivery (Sills et al., 2004a; Sills et al., 2009c). Yet, 
because the incidence of chromosomal abnormality is higher in embryos from patients 
experiencing multiple IVF failures (Voullaire et al., 2007), much attention has been 
focused on embryo genetics as the most important reason for poor IVF outcomes. 
Blastocyst nidation is impaired in the setting of embryo aneuploidy, making this the key 
step in overall reproductive outcome (Boomsma & Macklon, 2008; Walsh et al., 2009b). 
For example, when pre-implantation genetic diagnosis (PGD) data are studied from 
embryos obtained from patients who have experienced multiple IVF failures, aneuploidy 
is more often observed in the cycle following the initial failure (Pagidas et al., 2008). 
Thus, an impaired capacity to produce reproductively competent embryos is the critical 




3. Array CGH—Technique & Logistics 
Array comparative genomic hybridization (aCGH) accomplishes selection of euploid 
embryos for fresh transfer first by whole genome amplification of each embryo, 
performed on-site at the IVF laboratory using the SurePlex DNA amplification system 
(BlueGnome Ltd; Cambridge, UK) in accordance with manufacturer’s guidelines 
(Alfarawati et al., 2011; Yang et al., 2011).  
 
In brief, trophectoderm biopsy samples (1-2 cells) and control DNA (8 l each) are 
labeled with Cy3 and Cy5 fluorophores (BlueGnome Ltd; Cambridge, UK). Labeling 
time is typically three hours with DNA resuspended in dexsulphate hybridization buffer, 
before being placed on an array slide for hybridisation. After saline sodium citrate 
(SSC)/0.05% Tween-20 irrigation at room temperature, an additional ten minute wash in 
SSC is completed at room temperature. Slides are next washed in SSC for five minutes 
at 60°C and again for one minute at room temperature. A vacuum centrifuge is used to 
dry microarray slides with subsequent laser scanning at wavelength 10 m (Agilent 
Technologies; Santa Clara, USA).  
 
Microarray data are analyzed with BlueFuse software (BlueGnome, Cambridge, UK) to 
determine chromatin loss or gain across all 24 chromosomes. In general, aberrations are 
considered non-artifact if 15 or more probes deviated from normal limits as defined by 
the 24Sure platform. The published accuracy rate for this methodology when applied to 
trophectoderm cells is 95% (Alfarawati et al., 2011; Sills et al., 2012b). Embryo ploidy 
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data is usually ready early enough to allow fresh transfer of a single embryo on day six 
(morning).  
 
When multiple euploid blastocysts are available, the euploid blastocyst with the best 
morphology would be chosen for fresh transfer. Surplus euploid blastocysts are vitrified 
for future use (Liu et al., 2012a). As shown in Figure 1, aCGH represents an additional 
crucial step in the IVF treatment process, following fertilisation and biopsy, at a time 
when morphology alone would typically be used exclusively to select embryos for 
transfer. Since aCGH consumes only about 12 hours of laboratory time after embryo 
biopsy, this eliminates the need to freeze all IVF embryos after biopsy with shipment of 
the biopsy samples for off-site testing. Fresh (single) embryo transfer can be performed 
on day six, thus obviating the need for additional medication (and at least one month 
delay in treatment) associated with subsequent frozen/thaw embryo transfer (see Figure 
2). 
 
There is some controversy regarding the ideal developmental stage when embryo biopsy 
for aCGH should be performed (Yang et al., 2011). The reduced cellular mosaicism at 
day five (compared to day three) has led some centres to prefer biopsy at the blastocyst 
(d5) stage. When combined with trophectoderm biopsy and blastocyst vitrification, SNP 
microarray has resulted in high implantation rate and low miscarriage rates for some 
poor prognosis IVF patients (Schoolcraft et al., 2010). Prior to May 2012, there was no 
published experience with aCGH in selecting a euploid blastocyst for single fresh 







Figure 1. Integration of array comparative genomic hybridisation (aCGH) with the in vitro fertilisation sequence. This schematic depicts aCGH components 
and time requirements (in hours) for each: A) sample preparation and genomic amplification, B) labeling, C) hybridisation, and D) scanning/reporting.  Biopsy 
of embryonic trophectoderm at day five (blastocyst stage) is shown at Bx, and fresh single embryo transfer on day six corresponds to fET(d6). This protocol 
enables comprehensive chromosomal screening within 12 hours of biopsy, thus obviating the need for empiric cryopreservation of all embryos while off-site 






























Figure 2. Schematic of conventional IVF (above) and IVF with aCGH (below), indicating follicular recruitment/ovulation induction (A1,A2) and oocyte 
retrieval/ICSI (B1,B2) steps in each treatment sequence. Comprehensive chromosomal screening (ccs) occurs instead of traditional morphological assessment 
of embryos (m), identifying any aneuploid embryos (red x). This permits selection of a single euploid embryo (green check) for fresh transfer (C2) or 
cryopreservation (). Pregnancy rates nearing 70% have been reported after fresh transfer of one euploid embryo using this technique (fET(d6)) , with 
significant reduction in multiple gestation rate (Rmg).
2
1
Encouraging data now show a way forward to augment IVF with aCGH, and to do so in 
a highly cost effective manner (Sills et al., 2012b). 
 
A recent investigation (Yang et al., 2012) enrolled IVF patients willing to undergo fresh 
single blastocyst transfer with embryos randomised either to assessment by morphology 
alone, or by morphology plus aCGH. Researchers analysed 425 blastocysts via aCGH, 
and aneuploidy was present in 44.9%. These normal appearing embryos would have 
been considered suitable for transfer based on morphology, but chromosomal error 
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would have rendered them reproductively incompetent. As reported by Yang and 
colleagues (2012), the age-matched patient control group contributed 389 blastocysts 
which were assessed traditionally, by microscope only (no aCGH). This new approach 
substantially improved IVF efficiency, with clinical pregnancy rates increasing by 65% 
over the observed rate when conventional morphology alone was used to select single 
embryos for transfer (Yang et al., 2012).  
 
Of note, there were no twin or triplet pregnancies in either group. The clinical pregnancy 
rate was significantly higher in the morphology plus aCGH group compared to the 
morphology-only group (70.9 and 45.8%, respectively; p=0.017). The publication 
appearing in the journal Molecular Cytogenetics remains among its most highly-
accessed papers, and was the first to describe integrating embryo screening via aCGH 
with standard IVF and single blastocyst transfer (Yang et al., 2012). Such synergy 
between advances in genetics and embryology seems positioned to usher in a new era in 
the treatment of infertility (Fragouli & Wells, 2012; Sills et al., 2012b), although thus far 
there has been little awareness of the potential economic impact of these studies or how 
they might shape public health policy.  
 
Although the use of highly accurate molecular tests to identify genetic conditions has 
been established for some years (Sills et al., 2002 & 2007), expenses can vary depending 
on which test is used. The additional cost associated with including aCGH during IVF to 
assess multiple embryos in a cohort has been calculated at approximately $3000 (Yang 
et al., 2012; Sills et al., 2012b). It should be noted that current testing modalities permit 
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several embryos to be tested at the same time, depending on which aCGH platform is 
used. In contrast, average NICU costs typically exceed $3,500 per infant per day, and it 
is not uncommon for this figure to top $1M for a prolonged stay (Muraskas & Parsi, 
2008). California can be the first state to implement a health benefit programme that 
recognises the social and economic value of offering a regulated, public IVF plan as a 
way to manage these “first year of life” healthcare costs. Yet, to do so will require 




4.1. How Many Embryos for Transfer?—Current Regulations (International) 
Except for Sweden and Belgium (De Neubourg et al., 2006; Karlström & Bergh, 2007), 
all other jurisdictions permit the number of embryos for transfer to be whatever the IVF 
doctor and patient want, so the clinician’s role in this process is vital (van Peperstraten et 
al., 2008). While some may favour the unregulated flexibility where the number of 
transferred embryo is not legally limited (Gleicher, 2011), one noteworthy case in 
California focused negative attention on the undesirable outcomes associated with a very 
high number of embryos transferred and the associated preterm delivery of octuplets 
(Kern, 2009; Rosenthal, 2011). Resistance to regulating number of transferred embryos 
derives from principles of procreative liberty, patient and professional autonomy, and 
free-market economics (Gleicher, 2011). In contrast, others have countered that IVF 
physicians must fulfill their professional fiduciary responsibility to balance 
nonmaleficence and proper utilisation of limited health care resources with patient 
requests to transfer multiple embryos (Van Voorhis & Ryan, 2010).  
 
These two viewpoints represent interesting arguments for “self-pay” medical consumers 
in the United States. For IVF patients, the goal is simply to get pregnant quickly, thus the 
“freedom of choice” (unregulated) model has strong appeal. Indeed, when elective 
medical choices are influenced by free-market forces, the consumer’s interest in single 
embryo transfer can be very low because this approach is associated with reduced per-
cycle pregnancy rate (Le Lannou et al., 2006) and delayed “time-to-pregnancy” 
(Lukassen et al., 2005). When elective SET is undertaken on the basis of conventional 
morphology assessment alone, this consistently gives reduced delivery rates compared to 
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dual embryo transfer, a result demonstrated in every randomised clinical trial published 
to date (Forman et al., 2012). However, assuming the success rate with SET could be 
increased to approach that of double embryo transfer, then patient acceptance of single 
embryo transfer would surely improve (Leese & Denton, 2010). 
 
Even where rules governing embryo transfer are in effect, there has never been specific 
regulation addressing how the single embryo must be selected. Thus far, legislation has 
been silent on this matter perhaps because it represents a contentious, evolving area of 
reproductive genetics: there is no scientific consensus yet on the optimal method to 
determine the competency of the embryonic genome during IVF. Single nucleotide 
polymorphism (SNP) array and array CGH (aCGH) have both been validated as accurate 
methods to achieve comprehensive chromosome screening when embryo biopsy is 
performed on d3 for fresh transfer on d5 (Hellani et al., 2008; Fishel et al., 2010; 
Fioretino et al., 2011; Gutierrez-Mateo et al., 2011; Handyside, 2011).  
 
As California contemplates its own programme for subsidised IVF coverage where the 
number of transferred embryos is limited to one, looking to Belgium perhaps best 
illustrates how this could be implemented. A law regulating the number of transferred 
embryos there became effective in July 2003 (Salame et al., 2011). Belgian IVF 
regulations actually stipulate a strong preference for single embryo transfer, but 
provisions for exceptions do exist. Specifically, for patients age less than 35 years 
undergoing fresh non-donor transfers (i.e., not using cryopreserved embryos or oocyte 
donation), the first attempt is limited to one embryo for transfer. After the second IVF 
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attempt, a two embryo transfer is the maximum allowed. When the patient is age 35-40, 
a two embryo transfer is the maximum permitted for first and second IVF attempt, but 
three embryos may be transferred on the third cycle. As patient age approaches 43, there 
is no limit on the number of embryos transferred (Salame et al., 2011). Thus, single 
embryo transfer has been mandatory for IVF patients up to age 35 years in Belgium for 
nearly ten years; contrasting multiple gestation rates in this group before and after 
implementation of this policy is highly relevant to the current proposal. Belgium’s 
restriction in the number of embryos for transfer has led to a significant reduction of the 
multiple pregnancy rate, associated with a clinical pregnancy rate of 36.8% overall 
among IVF patients under age 36 (Salame et al., 2011).  This success rate with SET is 
similar to the clinical pregnancy rate observed in Belgian IVF patients who undergo a 
two-embryo transfer (37.5%, p>0.05), although the observed twinning rate is 
significantly lower (8.3 vs. 22.4%, p<0.001) (Salame et al., 2011). 
 
Of note, Belgian policies on embryo transfer (and ovarian stimulation) have not included 
any requirement for comprehensive chromosomal screening of embryos before transfer 
(the law was developed during a time when aCGH was not yet widely used in 
reproductive medicine), which could explain why overall pregnancy rates are lower than 
those reported when aCGH is used with IVF (Liu et al., 2012a,b; Sills et al., 2012b; 
Yang et al., 2012). Nevertheless, savings realised by the Government of Belgium from 
reductions in health spend associated with neonatal intensive care (and pharmacy 
savings) now enables the Belgian national insurance system to subsidise up to six IVF 
cycles for eligible patients up to age 43 (Salame et al., 2011). 
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Important improvements in comprehensive chromosomal screening of embryos have 
been reported in the decade since Belgium’s law was enacted. Experience with aCGH 
and IVF now shows that clinical pregnancy rates from IVF can nearly double even if 
only one (euploid) embryo is transferred (Liu et al., 2012a; Yang et al., 2012). This 
means that almost no IVF patient would require six fresh cycles, since each attempt can 
yield a pregnancy rate of about 70% (Liu et al., 2012a; Sills et al., 2012b; Yang et al., 
2012). Because IVF is so closely connected to the problem of multiple births, and 
considering the avoidance of iatrogenic twin, triplet and higher-order gestations would 
result in significant savings in health spending (Lukassen et al., 2004; Salame et al., 
2011), a critical appraisal of single embryo transfer following IVF and aCGH is now 
appropriate. 
 
Does government have an interest in the provision of this elective medical service? 
Connolly and co-workers (2009) developed a model to quantify the lifetime net tax 
position for the child (either naturally conceived, or born after IVF), and found a positive 
revenue gain for the government. Indeed, the only difference between the two scenarios 
(unassisted pregnancy vs. IVF) was confined to the additional cost of IVF required for 
conception. Using this formula, it was determined that an initial investment of £12,931 
for IVF would yield an 8.5-fold return to the state over the child’s taxpaying lifetime 
(Connolly et al., 2009). 
 
Before any new public health initiative may be considered, it is essential to anticipate 
costs and yields. When IVF was studied as a benefit under the remit of the National 
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Health Service, investigators from the United Kingdom (Connolly et al., 2009) described 
a health investment model embracing multiple factors. The researchers estimated 
discounted future net tax revenue to the government, based on average “investment cost” 
for IVF needed to add one extra taxpayer to the national population by achieving a 
singleton live birth. This analysis was based on the formula modified from Cardarelli 
and colleagues (2000): 
 
CL (t) = T(g) – E (t) – H (t) – C (t) – PS (t) 
 
where T(g) is gross tax revenue received, E(t) and H(t) correspond to the state’s 
education and healthcare expenditure, and C(t) represents child tax credits. Roles of 
government pension costs and privately-funded retirement pension are considered jointly, 
as taxation returns from private pension (from which the state receives additional 
revenue by pension tax) are factored as Ps(t). Accordingly, the net lifetime tax 
contribution to government may be estimated by CL(t). 
 
Yet revenue returns predicted by the Cardarelli formula have greatest traction when 
every IVF attempt is a success, and each pregnancy gives a singleton livebirth. 
Unfortunately, current IVF practice cannot realistically deliver this level of clinical 
service (Sills et al., 2009a). With an IVF treatment cost indexed at £12,931, and 
considering standard IVF in the United Kingdom typically costs about £3,500 per 
treatment (Sample, 2011) the formula clearly acknowledges the need for multiple 
attempts. Nevertheless, the predicted return could be substantially enhanced if IVF were 
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refined to produce higher pregnancy rates with a multiple gestation rate identical to the 
background population level. 
 
The impact of IVF on national birth rate and multiple gestation trends has been reported 
from other countries (Sills et al., 2010d), and California’s savings from avoiding IVF 
multiple gestation/preterm births from IVF may also be calculated. These projections are 
extrapolated from earlier work (see Table 1) where one vs. two embryo transfer costs 
were compared (Wølner-Hanssen & Rydhstroem, 1998).  
 
Table 1.  Selected women’s healthcare costs (historical) as a function of  
number of embryos transferred during IVF, per patient. 
 
 
  Embryos transferred (n)  
     
Cost element  One Two  
     
Sick leave  1830 4122 2292 
In-patient care  866 2785 1919 
Obstetrical care 
(delivery) 
 2760 4970 2210 
Neonatal care  1988 13279 11291 
Disability payments  3280 18130 14850 
     
Total  10724 43286 32562 
     
 
Notes: All costs reported in 1995 Swedish Krone. Table adapted from Wølner-Hanssen & 
Rydhstroem (1998). 
 
Additionally, where there is increased risk for offspring affected by chromosomal 
conditions (i.e., advanced maternal age), aCGH could provide participating patients with 
information on embryo ploidy status before transfer (Hellani et al., 2008). To be sure, 
society already carries much of the economic burden from complications associated with 
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multiple gestation, so governments have a compelling regulatory interest in how IVF is 
provided. The problem has been that, until now, there was no effective technology 
available to use with IVF to address these goals. Now that aCGH has been shown to fill 
this role and safely lift singleton pregnancy rates from IVF, continued provision of 
traditional IVF with multiple embryo transfers seems unnecessary. As shown in the next 
section, implementation of the current proposal in California would entail the state 
offsetting relatively small initial costs in the short term, with an expectation that 
substantial savings from reductions in “first year of life” healthcare spending are 





4.2. How Many Embryos for Transfer—Proposed Regulations (California) 
Interest in medical fertility treatments in general, and IVF in particular, among medical 
consumers in California remains strong. Since the first tabulation of national IVF data in 
1996, the number of pregnancies conceived and infants delivered in the United States 
with the assistance of IVF has risen nearly threefold (Sunderam et al., 2012)—a growth 
rate to which California has made substantial contributions. Sixty one IVF clinics 
operate in California alone, more than in any other U.S. state. In 2009, California 
residents initiated the highest total number of IVF cycles of any U.S. state.  
 
The economic impact of IVF with regards to multiple gestation and preterm birth is 
substantial. About half (47%) of all IVF deliveries are multiple gestation, compared to 
about 3% in the background population (see Table 2a). California and five other states 
accounted for nearly half (48%) of all American IVF births in 2009, highlighting an 
unbalanced geographic distribution of IVF utilization in the United States (Sunderam et 
al., 2012). Interestingly, despite the high absolute number of IVF cycles initiated in 
California, the state only ranks twelfth in the nation when the number of IVF cycles is 
measured against the total number of reproductive age women. Most likely, California’s 
lower per capita IVF consumption is due, at least in part, to the state not having a 
statewide mandate for IVF insurance coverage. 
 
Not having a state insurance mandate for IVF in California is a critical element in this 
analysis. Unfortunately, IVF coverage is rarely included in private health insurance plans 






   
 
 
  Table 2a. Distribution of multiple gestation deliveries after IVF in California (2009). 
 IVF multiple births Total multiple 
births 




% from IVF 
n (%) n (%) n (%) n (%) n (%) n (%) 






    Table 2b. Distribution of California IVF deliveries by gestational age at birth (2009). 
<37 weeks GA <32 weeks GA 32–36 weeks GA 
IVF All births % from 
IVF 
IVF All births %  from 
IVF 
IVF All births % from 
IVF 
n (%) n (%) n (%) n (%) n (%) n (%) 
2,405 31.9 53,956 10.2 4.5 413 5.5 7,948 1.5 5.2 1,992 26.4 46,008 8.7 4.3 
 
 
Notes:  IVF = in vitro fertilisation; HOM = higher-order multiple birth (i.e., triplets and higher order gestation); GA = gestational age. Total births tabulated by 
federal methods differ slightly from State of California vital statistics. Patients without a designated residency status were assigned to California if IVF treatment 
was performed within the state. This summary includes infants conceived from IVF initiated in 2008 and born in 2009, and infants conceived from IVF 
performed in 2009 and born in 2009. Source: U.S. CDC/National Center for Health Statistics, in Sunderam et al, 2012.
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Where state IVF mandates are currently lacking, attempts to minimise out-of-pocket 
costs have been linked to higher numbers of embryos transferred per patient (Jain et al., 
2002). Thus, insurance mandates for IVF appear to be associated with not only improved 
access to assisted fertility therapy, but also substantially fewer aggressive IVF treatments 
where lower numbers of embryos are transferred per procedure (Hamilton & McManus, 
2012; Jain et al., 2002).  
 
Importantly, 32% of all infants conceived by IVF in 2009 were low birthweight (<2,500 
grams), and 33.4% of all IVF babies were delivered preterm (see Table 2b). In California, 
the contribution of IVF births to all low birthweight deliveries ranges from 6.3% to 6.7% 
depending on which category of birthweight is considered (see Table 3a). Overall, 
California’s rate of preterm delivery was about 20.5% in 2009, which was somewhat 
lower than the national average (24.2%, in 2009). 
 
These data highlight the hazards of overestimating the impact of IVF on overall poor 
delivery outcomes. While transferring more than one embryo in IVF does influence the 
rate of multiple gestation and preterm delivery (see Table 3b), the prevalence of these 
poor outcomes cannot be ascribed solely to IVF because this treatment accounts for a 
relatively small fraction of total births (Sunderam et al., 2012). Of note, a recent study of 
preterm birth rates in the United States between 1989 and 2004 found that half the 







     Table 3a. Distribution of California IVF deliveries by low birthweight category (2009). 
<2,500 grams <1,500 grams 1,500–2,499 grams 
IVF births All births % from 
IVF 
IVF births All births % from 
IVF 
IVF births Total births 
(all) 
% from IVF 
n (%) n (%) n (%) n (%) n (%) n (%) 
 






Table 3b. Comparison of singleton delivery characteristics, IVF and unassisted conceptions in California (2009). 




IVF Singleton births Singleton births 
(all) 
% of IVF singletons 
to all singleton 
births 
n (%) n (%) 
 527,020 7,546 1.4 3,973 52.7 510,219 96.8 0.8 
         
 
Notes: IVF = in vitro fertilisation. Total births tabulated by federal methods differ slightly from State of California vital statistics. Patients without a designated 
residency status were assigned to California if IVF treatment was performed within the state. This summary includes infants conceived from IVF initiated in 
2008 and born in 2009, and infants conceived from IVF performed in 2009 and born in 2009. Source: U.S. CDC/National Center for Health Statistics, in 




While the report from the Born Too Soon Preterm Prevention Analysis Group did 
include a recommendation to decrease multiple embryo transfers during IVF as one of 
five specific initiatives to help resolve the preterm birth challenge (Chang et al., 2012), 
because the United States has no nationwide database to capture information on 
gestational age at delivery following IVF, the actual impact of IVF on preterm births 
cannot be known with precision (Sills & Collins, 2013). For California, general cost 
parameters for IVF may be extrapolated from the following relations: 
 
F(b) x F(c) = F(t) 
 
Where F(b) is the total number IVF cycles initiated in California, F(c) is the mean 
estimated cost per IVF cycle (invoiced at $13,000) and F(t) represents approximate total 
health spend on IVF for 2009; and 
         G(tm) 
G(b)  x G(c)           +           =  G(t) 
          G(<37) 
 
Where G(b) is total number of all California births in 2009, G(c) is aggregate cost for 
delivery and infant care [comprised of term birth costs G(tm) plus preterm (<37 weeks 
gestational age) birth costs, G(<37)], and G(t) is approximate total California health 
spend on all deliveries for 2009. A variation on this formula can also be used to estimate 
costs associated with IVF deliveries, although the ratio of term/preterm and multiple 
gestation births is altered. 
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Recently published California data give the following information for 2009:  
a) Total number of births = 526,744 
b) Total number of IVF cycles initiated (completed) = 18,405 (15,953) 
c) Births attributed to IVF = 7,546 
d) Low birthweight deliveries (total) = 71,604 
e) Preterm deliveries (total) = 107,912  
f) Low birthweight deliveries from IVF = 4,746 
g) Preterm deliveries from IVF = 4,810 
h) Estimated term delivery cost = $9,329 
i) Estimated preterm delivery cost = $51,600 
j) Cost of IVF per cycle (±aCGH) = $10,000 ±3,000 
 
The total number of California births registered in 2009 is reported as 527,020 (federal 
source) or 526,774 (state source). In this case, the state record was regarded as more 
accurate (State of California, 2012c) while the remaining entries are federally derived 
(Sunderam et al., 2012) or from clinic invoices where aCGH is offered on-site with IVF. 
While the numerical contribution made by IVF deliveries to the overall populations of 
low birthweight, preterm, and multiple gestation in California is minor, the downstream 
economic consequence of multiple embryo transfers in IVF is noteworthy.   
 
From a total of 18,405 initiated IVF cycles in California during 2009, about 87% 
proceeded to embryo transfer. For these patients, the mean number of embryos 
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transferred during IVF per cycle was never less than two, and this increased with patient 
age in a manner similar to the national trend as summarised in Table 4. 
 
    Table 4. Cycle characteristics and outcomes for U.S. IVF patients, by age (2009) 
 Patient age (years) 
 <35 35-37 38-40 41-42 43-44 
Total IVF cycles initiated (n) 42,384 21,860 22,144 9,845 4,857 
Implantations per ET (%) 35.3 25.9 17.2 9.1 4.2 
Pregnancies per initiated cycle (%) 47.4 38.7 30.1 20.3 10.7 
Livebirths per initiated cycle (%) 41.2 31.6 22.3 12.4 4.9 
Livebirths per retrieval (%) 44.3 35.3 25.8 14.9 6.2 
Livebirths per ET (%) 47.2 38.1 28.2 16.7 7.2 
Singleton livebirths per ET (%) 30.9 27.0 21.8 14.0 6.6 
Cancelled IVF cycles (%) 7.0 10.5 13.7 17.0 20.3 
Average ET (n) per patient 2.1 2.3 2.7 3.1 3.2 
 
Notes: IVF = in vitro fertilisation, ET = embryo transfer. All data derived from U.S. CDC 2009 Assisted 
Reproductive Technology Report for non-frozen (fresh) transfers involving non-donor gametes. No data 
were tabulated for patients age >44 years in this report. 
 
If aCGH had been incorporated with IVF in 2009 to facilitate SET (rather than number 
of transferred embryos being ≥ 2), then some of California’s 4,810 preterm birth 
outcomes resulting from IVF would have been replaced by less expensive term singleton 
deliveries. These adverse preterm outcomes may be avoided, but not eliminated entirely. 
This is because the background rate of preterm birth in California without IVF is not 
zero. As Chang and colleagues (2012) have reported, approximately half of all preterm 
births occur because of unknown factors independent of IVF. Analysis of 2009 
California birth data shows a background rate of approximately 20.5% of deliveries 
being preterm, in contrast to California’s preterm birth rate following standard IVF 
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which is ~63%. While it is not surprising that the aggregate health spend on IVF infants 
is quite small compared to the majority (non-IVF) infant population, the difference in 
proportional resource allocation between term and preterm babies is conspicuous (see 
Figures 3a and 3b). Accordingly, if 7,546 deliveries were attributed to IVF in 2009 (from 
(c), above) and all of these births resulted from single embryo transfer, then 20.5% of 
7,546 would still be expected to be preterm deliveries (Chang et al., 2012). This means 
that only about 1,547 preterm babies would have been delivered in 2009, instead of 
4,810. Avoiding 3,263 preterm births in 2009 would have saved California about $168M 
in NICU spending. 
 
Assuming the mean delivery cost per preterm infant is $51,600 (from (i), above), then 
the aggregate delivery costs for 1,547 preterm infants should total about $79.8M. The 
remaining babies “rescued” as term singleton deliveries from IVF (n=5,999) will require 
about $56M in care costs, for a total of $135.8M in overall delivery costs for all 
California IVF babies in 2009.  
 
Considering California’s actual health spend on the 4,810 actual preterm births from IVF 
in 2009 was at least $248M, and that the state spent about $25.5M for singleton term 
delivery, the intervention of single embryo transfer with IVF should recover about 
$137.7M in NICU overspend for 2009 (see Figures 4a and 4b). 
 
  





Figure 3b. Distribution of delivery costs in California by gestational age at birth 2009 (calculated).
Preterm deliveries (<37wks GA)
Births at ≥37wks GA$5.6B
$3.9B
Source: State of California, Department of Finance (2012). PT = preterm (<37wks at delivery). 
Background California population/unassisted pregnancy births (left) vs. California IVF births (right)  





 However, before realising $137.7M in savings, California must first offset the de novo 
costs of IVF with aCGH and single embryo transfer needed to reach this lower preterm 
delivery target. This means the $137.7M must be reduced by the total amount of state 
subsidy provided for IVF patients in California. From (j) above, this is $13,000 per 
treatment assuming no funding match by the IVF patient (because this projection 
considers only fresh transfers, costs associated with medications, embryo 
cryopreservation, and subsequent frozen/thaw embryo transfer are not included). Even if 
every IVF cycle initiated in California during 2009 (n=18,405) were matched with state 
monies amounting to 50% of total treatment cost (i.e., reducing IVF patient out-of-
pocket cost by half), the requisite initial investment from California ($119.6M) would be 
fully recovered and net an annual state revenue surplus of approximately $18.2M. 
 
Likewise, if aCGH had been available and incorporated with IVF to facilitate SET in 
2009 (rather than multiple embryo transfer), then some of California’s 3,566 multiple 
gestation births resulting from IVF would have been averted. Among California IVF 
patients, the observed multiple gestation rate was 47.3% in 2009, which is significantly 
higher than the 3.2% multiple gestation rate in the general California population.  
 
Thus, if IVF with aCGH and single embryo transfer had been available for all 7,546 IVF 
cases, then this treatment would not have inflated the multiple gestation rate and instead 
would have contributed only ~242 IVF births as twins, triplets or higher-order multiple 
gestation. The avoidance of 3,324 excess (iatrogenic) multiple gestation births (if these
  
 
Figure 4a. Distribution of delivery costs associated with 7,546 IVF births in California (2009, calculated).




Total delivery & infant care budget for IVF births = $221M. Source: State of California, Department of Finance (2012). 
  
$37M 
Figure 4b. Distribution of delivery costs associated with 7,546 IVF births in California (2009, calculated).
Anticipated total delivery & infant care budget assuming IVF with single embryo transfer = $80.6M.





Source: State of California, Department of Finance (2012) and Sunderam et al, (2012). 
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delivered before 37 weeks gestation and therefore properly classified as preterm 
deliveries), would yield an even more dramatic realignment of NICU resources. 
Modifying the previous formula, this may be estimated as follows: 
 
 
    G(tm)                                          G(tm) 
     H  =   G(b) x G(c)         +                    -     G(b) x G(c)          +                 -   F(c)/2 
               G(<37)       MET                            G(<37)         SET 
 
 
Where H is the projected savings recovered from all IVF births under SET conditions 
subtracted from current IVF deliveries and multiple embryo transfers (MET), factoring 
the programme cost of IVF. Specifically, delivery care costs in California when IVF is 
offered with multiple embryo transfers is about $221M (due to the significantly higher 
multiple gestation/preterm birth rate), compared to only $80.6M if IVF were exclusively 
performed with SET resulting in no disturbance in the expected 3.2% multiple gestation 
rate. Again, assuming California’s benchmark benefit plan includes a 50% matching 
formula to discount the patient’s out-of-pocket cost for IVF with aCGH by half, (F(c)/2, 
above) all costs to the state would be fully recovered—plus an annual net surplus of 












Figure 5. Summary of IVF delivery costs in
California (n = 7,546) stratified by gestational
type, after multiple embryo transfer (MET) or
array comparative genomic hybridisation with
single embryo transfer (aCGH+SET). The
distribution of multiple gestation (dark grey,
above) vs. singleton births (light grey, below)
after IVF is compared for each embryo transfer
approach. Delivery costs are presented in 2009
U.S. dollars (millions).
Since delivery expenditures for singleton births
average about 20% of multiple gestation delivery,
and because the multiple gestation rate with SET
is significantly lower compared to MET, delivery
costs following aCGH+SET would be expected to
be approximately $140.4M lower using this
embryo transfer strategy (dashed line, blue).
However, this recovery must be offset by
IVF+aCGH expense ($119.5M), before net
savings may be estimated.
Assuming treatment fees for all IVF cycles
initiated in California during 2009 (n=18,405)
were supplemented by a negotiated 50% state
matching grant (red bar), savings from averted
multiple gestation/preterm births after
aCGH+SET would be sufficient to defray
treatment cost plus provide >$20M in net revenue
to California (green bar).
4
3
Note that preterm birth and multiple gestation outcomes are not independent events, so 
the budget recoveries forecast from the two sample calculations above are not additive. 
Neither state nor federal data presently allow for a regression analysis to show how fresh 
SET after IVF with aCGH might affect multiple gestation and preterm birth. In other 
words, some singleton deliveries will still be preterm, and some twin pregnancies may 
deliver after 37 weeks gestation, but calculating frequencies of these special outcomes is 




Another matter to consider as embryo testing becomes routinely integrated with assisted 
fertility treatment is that the clinical effectiveness of IVF changes when comprehensive 
chromosomal screening of embryos is included. For example, significantly higher 
implantation rates following transfer of an embryo after genetic testing have been 
reported by multiple investigators (Schoolcraft et al., 2012; Sills et al., 2012b; Yang et 
al., 2012) and the effect appears consistent for IVF patients of various ages. This 
modification means that consumption of IVF cycles could be reduced because successful 
pregnancy can be reached earlier and with fewer attempts, even in the setting of 
mandatory SET policy. Using 2009 California data, this effect can be measured by 
calculating actual IVF treatment yield where 18,405 standard IVF cycles were initiated 
to give 7,546 deliveries (approximately 41%). In contrast, the pregnancy rate reported 
with IVF, aCGH and SET is increased to ~70% (Yang et al., 2012). Thus, the initiative 
described here could have provided California IVF patients all their births in 2009, but 
with 7,625 fewer cycles initiated—thus redirecting $99.1M of discretionary spending 
away from excess IVF consumption and back into California’s general economy. 
 
Any curtailment in treatment uptake projected from the significantly improved 
pregnancy rate using IVF with aCGH and SET must be balanced by the potential for 
heightened demand in California, a reasonable expectation if patient cost for this service 
is suddenly reduced by half. Even as total costs for IVF have increased over time, the 
number of patients seeking this treatment has continued to grow (Talaulikar & 
Arulkumaran, 2012). It is plausible that a sizable, latent population considering IVF 
which had previously deferred this treatment due to its excessive cost would now find it 
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more affordable, thus swelling demand substantially. Administrative intake procedures 
including defined medical eligibility requirements, proof of California residency, or 
mandatory waiting periods should be developed to maximise treatment benefit. 
 
Importantly, this proposal would not preclude or proscribe continued privately-funded 
IVF for patients who wish to maintain the status quo and pay for fertility treatment 
themselves. Conserving an open-market option for California’s private-pay IVF patients 
should not significantly attenuate the savings projected here. This is because when given 
the choice of a high pregnancy rate (~70%) from IVF with screened single embryo 
transfer as provided under the state IVF programme, some affluent California patients 
may regard this incentive as sufficiently strong to leave the private market. In the 
private-pay setting, aCGH with single embryo transfer has recently become an option, 
albeit underutilised. It may be that private insurance contracts eventually move to this 
model as a condition of assisted fertility treatment coverage, if these policy holders 
remain as the only residual sub-group of IVF transfers which continue to result in 
higher-order multiple gestation outcomes. 
 
The estimates discussed here are not without limitations. For example, the reports from 
which they are derived used surveillance data reported for each IVF procedure 
performed (not for individual IVF patients), so this analysis could not link procedures 
for patients who initiated multiple IVF cycles. Also, the contribution of IVF to multiple 
gestation may be overestimated because stillborn infants were included in the tabulation 
of multiple births. Perhaps most importantly, data are available only for individuals 
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seeking IVF during the study period, and cannot ascertain individuals or couples with 
infertility who did not avail of IVF for personal, financial, or other reasons. Note that 
these calculations are based on a hypothetical 50% state subsidy to enable IVF treatment 
for California patients at a level where out-of-pocket costs would be cut by half. Other 
funding formulas are conceivable. While some patients may still not be able to afford 
IVF even at the discounted rate with government assistance from California, the impact 
of demand elasticity and price-for-service was outside the scope of this analysis. Except 
for industry reports that are not publicly available, very little data exists on individual 
consumer demand and personal income as reported by IVF patients. Notwithstanding 





5. Bioethical Considerations & Reproductive Policy Concerns 
Studies of public opinion and social response concerning offering access to a state 
subsidised IVF program where “terms and conditions” apply are underway, but the 
proposal’s public reception in California is likely to be favourable and similar to that 
presently voiced in support of conventional IVF. To be sure, even established health 
policies regarding reproductive issues rarely meet with universal acclaim (Dickens, 
2005) and some criticism from religious, feminist, or disability-rights advocates could 
follow this initiative. Perhaps the most controversial aspect of the current proposal 
entails setting boundaries on how information obtained from comprehensive 
chromosomal screening of embryos may be used.  
 
For example, recognising that IVF patients desire a healthy child from their pregnancy, 
what will be the disposition procedure for any abnormal or diseased embryos which the 
state has helped identify by aCGH (Piyamongkol et al., 2006; Altarescu et al., 2011)? 
Should state resources be part of a treatment which allows IVF patients to select the sex 
of their offspring (Sills & Palermo, 2002b)? Could IVF patients use this programme to 
begin a pregnancy expressly to have a “tissue matched” baby, so that a suffering, older 
sibling requiring a transplant might have a donor and survive (Samuel et al., 2009; Lai, 
2011)? Can the programme be expanded to include IVF with donor gametes, and, if yes, 
how will the matter of donor compensation (if any) be resolved? Such concerns raise 
sensitive and complex questions when basic IVF is funded entirely at patient expense; 
involving public money will no doubt focus increased attention on these bioethical 
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issues and will require considerable multidisciplinary input to settle (Farsides & Scott, 
2012). 
 
Yet in 2004, the California public encountered a question of related complexity. Voters 
were asked if public funds should be used to support controversial, high-technology 
biomedical research. “Proposition 71” established the California Institute for 
Regenerative Medicine to award $3 billion in competitive, peer-reviewed grants to 
advance stem cell research (including human embryonic stem cell work). Authorising 
the most expansive state-funded medical research initiative in U.S. history, this ballot 
initiative passed with nearly 60% support (Burgin, 2010). Although implementing partial 
state subsidies to enable IVF treatment in California with aCGH and SET as proposed 
here would require a far smaller budget (and would provide clinical results much sooner), 




6. The Economics of IVF & Insurance Under ‘Obamacare’   
The financial stress associated with IVF is difficult to overstate. Prohibitive out-of-
pocket costs make many who need IVF unable to initiate or complete this therapy. The 
clinical or institutional expense is, unfortunately, just one aspect of treatment since 
pharmacy costs associated with IVF often increase substantially the overall expense to 
patients. Research suggests that fertility patients will sometimes choose to self-
administer more of the prescribed injections, if it might mean saving enough money to 
make IVF more affordable (Sills et al., 2012a). Although previous research has shown 
that gonadotropin use during IVF may be lower where SET is mandated (Salame et al., 
2011), this cost element was not included for coverage in the proposed initiative for 
California. Previous research has recognised the challenge of gonadotropin cost and 
others have outlined workable strategies to include this expense in an overall IVF budget 
(Hildebaugh et al., 1997; Stassart et al., 2011). Should actual health savings for 
California exceed projected levels, then a pharmacy benefit could be added in a 
subsequent revision.  
 
In the fortunate circumstance where individuals do have access to IVF either by a 
mandatory state requirement or a defined employee health benefit to offset these 
treatment costs, patients are acutely aware of the vulnerable nature of such coverage. 
Access to IVF, and therefore the ability to begin or grow a family, will be disrupted if 
patients move to another state or if they lose their job. This pressurised situation helps 
explain why some patients are not dissuaded from IVF merely because a twin pregnancy 
could result. Multiple studies have demonstrated that a twin outcome from IVF is not 
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only acceptable, but desirable (Gleicher & Barad, 2009; Walsh et al., 2009a; Fiddelers et 
al., 2011). 
 
Even when the number of transferred embryos is limited to two (a policy generally 
regarded as conservative clinical practice in USA), the risk for dizygotic twinning after 
IVF must be acknowledged as significantly higher than the twinning risk observed in a 
background population of unassisted conception (Sills et al., 2000 & 2010d). IVF 
patients are informed that health costs for twins and triplets may be 3- and 10-fold higher, 
respectively, compared to singleton deliveries (Ledger et al., 2006), but in clinical 
practice this rarely dampens the enthusiasm for twins (Gleicher & Barad, 2009). One 
reason consumers may be focused more on attaining “pregnancy at any cost” is that after 
delivery, the reimbursement system changes so that supportive care, infant surgery, and 
other neonatal health resources become covered expenses, eligible for state support or 
insurance coverage. In other words, while treatment expense for IVF in California is 
almost always funded privately, the substantial downstream costs deriving from any 
multiple gestation or preterm births are shared by society.  
 
Linking insurance coverage or state subsidy with the objective of improving access to 
IVF is not an entirely new concept. In the United States, however, a SET stipulation as a 
condition of assistance with IVF treatment does not currently exist, most likely due to 
inadequate technology to identify reproductively competent embryos with precision. 
Even in states where insurance coverage for IVF is mandated for certain groups (e.g., 
Illinois, Maryland, Massachusetts and Rhode Island), SET is not compulsory. Elsewhere, 
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the provision of IVF is on the basis of the patient’s own ability to pay (Neumann, 1997). 
It was against this backdrop that “Obamacare” entered the national vocabulary to 
describe a method to provide substantial and serious reforms for the American 
healthcare system.   
 
On June 28, 2012, the Supreme Court of the United States issued a landmark ruling in 
the matter of National Federation of Independent Businesses v. Sebelius (2012), which 
challenged the constitutionality of the Patient Protection & Affordable Care Act, 2010 
(PPACA). This 5-to-4 decision affirmed the constitutionality of key elements of 
“Obamacare” and returned the national discourse on universal healthcare back to the 
political arena (Friedman, 2012). While the Court cleared a significant obstacle for 
providing universal healthcare in USA, it was not designed to consider specific types of 
treatment which should be provided. In fact, neither “Obamacare” itself nor the ruling 
from the nation’s highest Court provided any guidance to American fertility patients. For 
patients seeking elective fertility treatment, the most important changes brought by 
PPACA are that lifetime limits (“benefit caps”) for covered services were eliminated, 
and that pre-existing conditions cannot be used as a basis to deny health insurance 
coverage (Bazer, 2012). Coverage areas under “Obamacare” were reserved for the U.S. 
Secretary of Health and Human Services (HHS) to define, and this federal department 
established the essential health benefits (EHB) across ten categories as shown in Table 5. 
 
In compliance with the PPACA, each state has nominated its own insurance model in 
accord with this ten-part framework, to define the minimum coverage offered by all 
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insurers operating in that particular state. As expected, the role of the EHB was 
immediately recognised as central to the practical deployment of “Obamacare” since the 
EHB is the local mechanism by which each state defines patient benefits. With many 
vested interests in play (and frequently in open competition with each other), negotiating 
the EHB became a politically and socially charged endeavour (Iglehart, 2011).  
 
         Table 5. Health insurance coverage areas required by the U.S. Patient Protection &   
                         Affordable Care Act, 2010 
________________________________________________________________ 
 
(1) Ambulatory patient services 
 




(4) Maternity & newborn care 
 
(5) Mental health & substance use disorder services  
                                     (behavioural health treatment) 
 
(6) Prescription drugs 
 
(7) Rehabilitative and habilitative services/devices 
 
(8) Laboratory services 
 
(9) Preventive/wellness services and chronic disease management 
 
(10) Paediatric services, including oral and vision care 
             ______________________________________________________________ 
     
An expert panel recommended that a “structured interactive process” be developed at the 
federal level to advise HHS on balancing the “tensions between comprehensiveness and 
affordability.” This committee consistently recognised that if the chronic problem of 
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rising health care costs were not adequately addressed, the most laudable goal of 
PPACA—to help the uninsured American population—is likely to be undermined. 
 
California’s essential health benefit was codified in Senate Bill (SB) 951, signed by 
Governor Edmund G. Brown Jnr. on September 30, 2012. This mandated that all small 
group and individual health insurance policies issued, amended, or renewed in the State 
of California must be identical to the health benefits covered by the “Kaiser HMO 30” 
plan (see Table 6), effective January 1, 2014 (State of California, 2012a). The legislation 
also prohibits any California insurer from modifying the list of mandatory benefits, even 
if such substitutions are budget neutral (State of California, 2012b).  
 
Because the benchmark plan selected by California specifically excludes the advanced 
reproductive technologies, fertility patients in California cannot look to “Obamacare” to 
improve access to IVF treatment at this time. The enactment of SB 951 does not mean 
that California is prohibited from including IVF in its “Benchmark Plan” in the future, 
only that there is no mandate for California to do so now. Benefits and services can be 
modified by the California General Assembly in 2015. As data from new technologies 
become available, each state’s benchmark plan is encouraged to be “more fully 
evidence-based, specific, and value-promoting over time” (Institute of Medicine, 2011). 
In California, this directive could be influenced by one recent study of more than 90,000 
fresh, non-donor IVF cycles comparing outcomes between states that mandated IVF 
coverage with those that did not (Martin JR et al., 2011). Interestingly, “free-market” 
states (no mandate) achieved a higher pregnancy rate (38.8% vs. 35%) and live-birth rate  
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                            Table 6.  California’s State EHB ‘Benchmark Plan’ (SB 951), 
                                              2012 Coverage detail. 
 
Component Cost to Patient 
  
Annual deductible 0 
Pharmacy deductible 250 for non-generic 
(brand) prescriptions 
Annual out-of-pocket maximum 
(individual/family) 
3,000/6,000 
Clinic visits (unless only for preventive & 
maternity) 
30 co-payment 
Preventive care & PNC 0 
Infertility treatment (IVF, ICSI, TESE) [Excluded] 
OT/PT & speech therapy 30 
Most laboratory tests & basic radiology 10 
MRI/CT/PET (complex radiology) 50 
Outpatient surgery 200/procedure 
A&E visits (waived if direct hospital admission) 100 
Ambulance 75 
Prescriptions – generic equivalent 10 (up to 100-day 
supply) 
Prescriptions – brand specific 35 (after pharmacy 
deductible) 
Hospital care – accommodation, tests, supplies, 
therapies 
400/day 
Hospital care (up to 100 SNF care days) 0 
Mental health services – outpatient 30 individual/15 group 
Mental health services – inpatient 400/day 
Chemical dependency services – outpatient 30 
Chemical dependency services – inpatient  
(detox only) 
400/day 
Select DME, prosthetics, orthotics, optical Not covered, but 20% 
off on glasses & 
contacts purchased 
from Kaiser 
Vision exam 0 
Home health care (up to 100 2hr visits) 0 
Hospice care 0 
  
 
All costs reported in US$ (2012).  
Notes: EHB – essential health benefit, SB – Senate Bill (California General Assembly), PNC – 
prenatal care,  IVF – in vitro fertilisation, ICSI – intracytoplasmic sperm injection, TESE – 
testicular sperm extraction,  OT/PT – occupational therapy/physical therapy, SNF – skilled 




(32.2% vs. 29.1%) than states with an IVF mandate, but these results came at the 
expense of a significantly higher twin (28.1% vs. 26%) and triplet rate (3.9% vs. 3.4%) 
in the nonmandated states. Not surprisingly, the mean number of embryos transferred 
was significantly higher among nonmandated states (2.6 vs. 2.2).  
 
California leadership could find guidance from prior research on mandated IVF coverage, 
the transfer of fewer embryos, and lower rates of multiple pregnancies and births, 
particularly in the younger age groups (Martin JR et al., 2011). It should be emphasised 
that such results from IVF were attained in the absence of any routine comprehensive 
chromosomal screening of embryos. Outcomes with standard elective SET (without any 
genetic assessment to guide which embryo is selected for transfer) can permit 
subsequent FET cycles, where a single thawed embryo is transferred on each occasion. 
Although this approach can work for some patients (Milne et al., 2010), for any one 
transfer SET has been found to yield about a one-third loss of success rate relative to 
dual embryo transfer (Roberts et al., 2010), and necessarily increases the “time to 
pregnancy” and overall treatment interval for IVF patients. 
 
A key recomm1endation of the IOM Committee on Defining and Revising an Essential 
Health Benefits Package for Qualified Health Plans (Institute of Medicine, 2011) 
specifically states that, beginning in 2015, the HHS Secretary should update the EHB 
package to make it more fully evidence-based, specific, and value-promoting, with an 
emphasis on cost analysis. For California, “Obamacare” will almost certainly result in 
significant additional demand for healthcare as more women gain insurance coverage 
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(Gee & Rosenbaum, 2012), and the funding for these extra services will need to come 
from somewhere. Regarding first-year-of-life care for multiple gestation and preterm 
birth, California already allocates considerable resources to provide these services. The 
data presented here show that aCGH with IVF and SET is one way to lower the 
healthcare burden associated with some of these “super-utilisers”, so that the millions of 
dollars saved could be used to offset partially the costs of other State of California care 
obligations enumerated by “Obamacare”. Just as with empirical research in other 
disciplines, it will be impossible to audit uptake of any social service until it has been 
identified, measured, and defined (Webley, 2010); a public deliberative process should 
inform choices about how to configure the updated package (Igelhart, 2011). It seems 
unlikely that the U.S. Health Secretary will modify the EHB to include fertility services 




7.  IVF and Population Growth 
What is the source of American population growth? Only about 1 in 75 new births in the 
United States is from IVF (Fuller, 2012). In contrast, the foreign-born population in the 
United States has tripled since 1970 (Capps et al., 2005). Even though a tiny minority of 
Americans avail of IVF and its traditional multiple embryo transfers, the number of IVF 
cycles initiated has increased every year since the treatment became available. In the 
meantime, the frequency and pattern of multiple births has changed dramatically, with 
the twinning rate rising 70 percent between 1980 and 2004 (Martin JA et al., 2011). 
Perhaps paradoxically, this upward trend in multiple gestation has occurred against a 
background of gradually falling national fertility rates. For example, the total U.S. 
fertility rate was 2.0 births per woman in 2009, but this dropped to 1.9 the next year and 
is now well below the replacement fertility level of 2.1. Similar changes (declines or 
plateaus) of fertility rates have been reported in Ireland, Italy, Spain, Sweden, and other 
European countries (Mather, 2012). 
 
Declining fertility in the U.S. is primarily being driven by a trend among young adults to 
postpone childbirth (Mills et al., 2011). That so many of these individuals become IVF 
patients, and eventually mothers to twins, triplets, and higher-order multiple preterm 
births, is reflected in the delivery statistics discussed previously (Talaulikar & 
Arulkumaran, 2012). In 1970, births among women in their 20s were significantly more 
numerous than those from women in their 30s. But, by 2009 the birth rate among U.S. 
women ages 30 to 34 (97.5 births per 1,000 women) exceeded that for women ages 20 to 
24 (96 births per 1,000 women)—a major demographic shift for the United States. 
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Among very young mothers in the U.S., the same pattern is evident: the (2010) birth rate 
among teens dropped to 34 births per 1,000 females ages 15 to 19—the lowest level ever 
recorded for this group in the United States (Mather, 2012). 
 
As impressive as IVF technology may be, attention to the opposite end of the life 
spectrum finds changes even more consequential for population growth. Quite 
independent of IVF utilisation (but not entirely unrelated), human mortality has 
decreased so substantially that the difference between hunter-gatherers and our lowest 
mortality populations is now greater than the difference between hunter-gatherers and 
our closest evolutionary ancestors in the animal kingdom, the wild chimpanzee. Most of 
this reduction in human mortality has occurred since 1900, experienced by only about 
four of the approximately 8,000 human generations that have ever lived (Burger et al., 
2012). As infertility was once though intractable, the concept of old-age mortality also 
has been significantly re-focused (Sills et al., 2001), such that life expectancy is no 
longer approaching a limit. Indeed, current evidence suggests that human ageing is 
plastic (Vaupel & Kistowski, 2005) and that survival may be extended by various 
genetic changes and non-genetic interactions. 
 
These demographic observations still must consider pro-natal technologies such as IVF 
carefully, because fertility and mortality are the two critical factors determining 
population size and age structure, and these usually do not change abruptly without 
famine, pandemic, or war (Feng, 2012). One exceptional case is China, where 30 years 
of severe policies limiting births (Sills et al., 1998) have had the dramatic effect of 
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curtailing population growth to among the lowest in the world (Feng, 2012). But in any 
country, reduced fertility coupled with rising longevity will cause the proportions of 
elderly to increase sharply and limit the supply of youthful labour to some extent. Even 
the oldest national populations of today will experience a doubling or more in their old-
age dependency ratios in the coming decades (Lee & Mason, 2010) irrespective of IVF 
utilisation. For populations with low or negative growth, policies to address ageing and 
very low fertility are of central importance. The current proposal addresses the fertility 
component to harmonise with other calls to improve efficiency of health spending, to 






The U.S. population is now characterised as decreasingly fertile, but with more multiple 
gestation births and significantly longer lifespans compared to prior generations. Acting 
with other socioeconomic factors, these characteristics exacerbate an unprecedented 
crisis in the American healthcare system. No single proposal can expect to address all 
facets of America’s healthcare budget crisis. Yet, key sectors must be encouraged to 
implement creative solutions in their domain with a view to manage costs more 
effectively. Here, comprehensive chromosomal screening of embryos on day five, 
integrated with IVF and single fresh embryo transfer is proposed for California to 
resolve two distinct but interrelated health system objectives: Reduction of “first year of 
life” health spending associated with multiple gestation and preterm births from IVF, 
and, equalisation of access to IVF without regard to ability to pay by means of a 
qualified state subsidy. It is unusual when two healthcare problems are fixable with a 
single policy initiative; it is exceptional when that policy conserves resources which are 
already limited. 
  
Reducing public health spending remains the focus of some budget strategies, and 
application of an integrated aCGH protocol with IVF and fresh SET should warrant 
consideration. Although extended embryo culture and blastocyst transfer are often 
considered as a way to “naturally select” embryos (Sepúlveda et al., 2011), this strategy 
has a low efficiency in identifying euploid embryos for transfer. In America, individual 
states can develop unique public health insurance programmes which may be used as 
experimental models influencing the entire nation (Larson & Williams, 2003; Romney, 
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2007). The present analysis is the first to demonstrate how a social health investment by 
California in IVF, aCGH from embryos biopsied on day five, and fresh SET being can 
be more than recovered by downstream savings, because health spend is conserved when 
costs of higher-order multiple gestation deliveries are avoided in favour of singleton 
births from IVF. This approach will not be considered in a policy vacuum, and other 
initiatives can also help by working in a complementary manner. For example, S965 in 
the U.S. Senate/HR 3522 in the U.S. House of Representatives (the “Family Act”) is one 
legislative effort which creates a new federal tax credit for infertility patients. The 
proposed credit would be based on 50% of IVF out of pocket costs, up to a lifetime 
maximum benefit of $13,360 (U.S. Library of Congress, 2012). A federal tax credit as 
proposed by the “Family Act” could be coordinated with a related state initiative in 
California to emphasise the role of aCGH and SET with IVF. 
 
Until aCGH emerged as a reliable and precise procedure to identify reproductively 
competent embryos in IVF, any reproductive health policy mandating SET would be 
impractical and poorly accepted by consumers. This proposal shows how rapid, on-site 
aCGH can bring single embryo transfer IVF pregnancy success rates approaching 70% 
within reach (Sills et al., 2012b; Yang et al., 2012) even for poor prognosis IVF patients 
(Liu et al., 2012b). Now that such data are available, it is essential that patients, 
providers, and policymakers understand the hazards (medical and economic) of 
continued multiple embryo transfer with IVF (Sills & Collins, 2013). California’s EHB 
schedule, set for revision in 2015, should include an economic analysis of statewide 
hospital encumbrances associated with neonatal “super utiliser” births after IVF 
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treatment. Specifically, for every preterm birth averted when SET is performed, 
California’s downstream health spend per infant could be reduced by about one-fifth 
($51,600 vs. $9,329). While other states already require insurance coverage for IVF, 
none address the multiple gestation or preterm birth problem by restricting the number of 
fresh embryos transferred after comprehensive chromosomal embryo screening. 
California can do better. Cost recovery in California’s health spending can be achieved 
with a pilot programme providing this service for qualified residents.  
 
California’s investment in aCGH with IVF and SET makes economic sense because the 
initial fertility treatment cost is always dwarfed by the subsequent healthcare burdens 
associated with preterm birth and multiple gestation. If a 50% matching program for IVF 
with aCGH and SET were available in California as proposed here, the grant amount per 
patient ($6,500) would be an effective way to reduce the state’s rate of preterm and 
multiple gestation births in this population—thus reducing the frequency of (and 
possibly mitigating maternal requests for) cesarean delivery (D’Souza & Arulkumaran, 
2013). The approaching 2015 target to modify the California Insurance Code 
(benchmark health plan) presents an opportunity to recast the regulatory framework to 
enable this approach. Additional impact studies are anticipated to validate policy goals 
and to determine administrative procedures to facilitate implementation as the EHB 
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